Y-mAbs Therapeutics, Inc. YMAB
8.61 0.00 (+0.00%)
At closeSep 16, 2025, 4:00 PM EDT
8.61 Day range 8.61
6.48 52-week range 20.90
News
zacks.com Y-mAbs Therapeutics, Inc. (YMAB) Now Trades Above Golden Cross: Time to Buy? After reaching an important support level, Y-mAbs Therapeutics, Inc. (YMAB) could be a good stock pick from a technical perspective. YMAB recently experienced a "golden cross" event, which saw its…
globenewswire.com Y-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB NEW YORK CITY and NEW ORLEANS, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating…
benzinga.com Deal Dispatch: Performance Food Group And Claire's Lead A Week Of Big Auctions, Retail Woes Performance Food rejects offer; Lufthansa drops Air Europa bid; NFL inks deal with ESPN; Claire's files bankruptcy amid retail struggles.
zacks.com Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.21 per share a year ago.
businesswire.com Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public Shareholders MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Y-mAbs (NASDAQ: YMAB) for possible breaches of fiduciary duty and other violations of law in its transaction with SERB Pharmaceuticals.…
fool.com Y-mAbs (YMAB) Q2 Revenue Falls 14% Y-mAbs Therapeutics (YMAB), a biopharmaceutical company focused on developing and commercializing antibody-based cancer therapies, reported its second quarter 2025 results on August 8, 2025. The…
globenewswire.com Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments PRINCETON, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and…
benzinga.com Earnings Scheduled For August 8, 2025 
prnewswire.com $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) NEW YORK , Aug. 7, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is…
businesswire.com Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
globenewswire.com Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025 PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and…
zacks.com YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains? YmAbs Therapeutics (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price…
https://thefly.com Y-mAbs Therapeutics upgraded to Equal Weight from Underweight at Morgan Stanley Morgan Stanley upgraded Y-mAbs Therapeutics to Equal Weight from Underweight with a price target of $8.60, up from $7, after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per…
https://thefly.com Y-mAbs Therapeutics downgraded to Hold from Buy at Canaccord Canaccord downgraded Y-mAbs Therapeutics to Hold from Buy with a price target of $8.60, down from $26, after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in cash.
https://thefly.com Y-mAbs Therapeutics downgraded to Perform from Outperform at Oppenheimer Oppenheimer analyst Jeff Jones downgraded Y-mAbs Therapeutics without a price target to Perform from Outperform after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in…
https://thefly.com Y-mAbs Therapeutics downgraded to Hold from Buy at Brookline Brookline analyst Kemp Dolliver downgraded Y-mAbs Therapeutics to Hold from Buy with an $8.60 price target after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in cash.
https://thefly.com Y-mAbs Therapeutics downgraded to Hold from Buy at Truist Truist downgraded Y-mAbs Therapeutics to Hold from Buy with a price target of $8.60, down from $14, after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in cash.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
prnewswire.com Shareholder Alert: The Ademi Firm investigates whether Y-mAbs Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders MILWAUKEE , Aug. 5, 2025 /PRNewswire/ -- The Ademi Firm is investigating Y-mAbs (NASDAQ: YMAB) for possible breaches of fiduciary duty and other violations of law in its transaction with SERB…
businesswire.com YMAB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Y-mAbs Therapeutics, Inc. Is Fair to Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) to SERB Pharmaceuticals for $8.60 per share in…
globenewswire.com SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics Acquisition to Include Naxitamab-gqgk DANYELZA ® ( Naxitamab-gqgk) , Further Broadening SERB's Rare Oncology Product Portfolio Transaction Expands SERB's Investment in the U.S. SERB to Commence…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session 
zacks.com YmAbs Therapeutics (YMAB) Upgraded to Buy: Here's What You Should Know YmAbs Therapeutics (YMAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com Earnings Scheduled For May 13, 2025
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com Earnings Scheduled For March 4, 2025
- benzinga.com Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
benzinga.com Earnings Scheduled For February 29, 2024 Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session - benzinga.com Earnings Scheduled For November 13, 2023 Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
- benzinga.com Earnings Scheduled For August 10, 2023 Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023
- benzinga.com Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease.
- benzinga.com Earnings Scheduled For May 8, 2023 Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For April 3, 2023
benzinga.com Earnings Scheduled For March 30, 2023 Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million.- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 469 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 175 stocks hit new 52-week lows.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
- benzinga.com Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday.
- benzinga.com Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know Editor's note: This story has been corrected to reflect that the FDA deferred action on Amicus Therapeutics' Biologics License Application.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 85 stocks hit new 52-week lows.
- benzinga.com Why Sonnet BioTherapeutics Shares Surged Over 66%; Here Are 63 Biggest Movers From Yesterday Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) climbed 66.4% to close at $1.93 on Monday after the company announced an agreement with Janssen for the evaluation of three Sonnet product…
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's session, 96 stocks hit new 52-week lows.
- benzinga.com Why Global Payments Shares Are Trading Lower By Around 8%? Here Are 41 Stocks Moving In Monday's Mid-Day Session Gainers 1847 Holdings LLC (NASDAQ: EFSH) shares surged 72.7% to $3.25 after the company reported it sees over $60 million in revenue and over $7 million in cash flow from operations in 2023 from its…